Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Fig. 1

Kinase selectivity of the Bruton’s tyrosine kinase (Btk) inhibitor, HM71224. a Kinome Binding Tree Spot analysis of HM71224 based on Scan Max data (DiscoveRx). HM71224 selectively bound to Btk (a TEC family kinase) at a concentration of 2 μM (indicated by red circles). b Selectivity of Btk for a screened panel of kinases. *TEC family kinase (TFK), EGFR epidermal growth factor receptor, JAK Janus kinase, BMX bone marrow kinase on chromsome X, TK tyrosine kinase, TKL tyrosine kinase-like, STE homolog of Sterile, CK1 Casein kinase 1, AGC protein kinase A, G, and C families, CAMK Ca2+/calmodulin-dependent protein kinase, CMGC cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSK), CDK-like kinases, BLK B-cell lymphocyte kinase, ITK IL2-Inducible T-Cell Kinase, JAK3 Janus kinase 3, LCK lymphocyte-specific protein tyrosine kinase, CSK C-Src Tyrosine Kinase

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us